Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction

Shoumiao Li; Jiaxin Liu; Hui Li; Jing Wang

doi:10.1080/07853890.2025.2526109

November 30, 2025Annals of MedicineOpen Access

Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction

View Full Paper

Ask AI

Bookmark

Share

Key Points

High NORAD expression indicates poor prognosis in neoadjuvant chemotherapy for adenocarcinoma.
Patients with elevated NORAD may experience reduced chemotherapy effectiveness and treatment resistance.
Observational analysis of treatment responses in adenocarcinoma linked NORAD levels to chemotherapy outcomes.
Elevated NORAD levels in this cohort highlight potential predictive markers for chemotherapy success.

Implication

High NORAD expression predicts poor response to neoadjuvant chemotherapy in adenocarcinoma, suggesting treatment resistance mechanisms.

Abstract

High pretreatment NORAD expression is an independent risk factor for poor response to neoadjuvant chemotherapy. Downregulating NORAD restores oxaliplatin sensitivity in resistant cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/6930dc78ea1aef094cca221f https://doi.org/10.1080/07853890.2025.2526109

View Full Paper

Ask AI

Bookmark

Share

Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction

Key Points

Implication

Abstract

Discussion

Cite This Study

Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading